Why Dermatologists Are Rethinking the 5% Ceiling on Minoxidil

New evidence challenges the long-standing 5% cap on topical minoxidil, as 7% and 10% formulations show promise for hair loss non-responders.

Microscopic view of hair follicle biology and minoxidil concentration research

For thirty years, the dosing story of topical minoxidil has been remarkably simple: 2% for women, 5% for men, nothing higher. That ceiling was set not by evidence of harm at greater concentrations but by the limits of what regulators approved in the early 1990s, when the FDA cleared 5% solution based on a single key trial showing it outperformed the 2% formulation by 45% in nonvellus hair counts over 48 weeks (Olsen et al., Journal of the American Academy of Dermatology, 2002). Nobody ran large-scale trials at 7% or 10%, so 5% became the default maximum. The science stopped at a regulatory boundary, and clinical practice froze there too. Now, a growing body of research is thawing that assumption, and the results are forcing a harder question: have we been undertreating a significant proportion of hair loss patients for decades?

The 60% Problem

The case for higher concentrations starts with minoxidil’s most awkward statistic. Roughly 30 to 40% of patients with androgenetic alopecia respond meaningfully to standard 5% topical minoxidil, depending on how “response” is defined (Badri et al., StatPearls, 2024). That leaves a majority of users with results ranging from modest to nonexistent, many of whom abandon treatment within a year. The standard clinical advice for these patients has been to add finasteride, switch to oral minoxidil, or accept diminishing returns. But the question of whether a higher topical concentration could convert some of those non-responders into responders went surprisingly unexamined until recently.

The logic is straightforward. Minoxidil is a prodrug. It does nothing on its own. When applied topically, it must be converted by the enzyme sulfotransferase (specifically SULT1A1) in the outer root sheath of the hair follicle into minoxidil sulfate, its active metabolite. That metabolite opens ATP-sensitive potassium channels in vascular smooth muscle and dermal papilla cells, causing membrane hyperpolarization that triggers follicles to enter anagen, the active growth phase. A higher local concentration of the prodrug could, in theory, compensate for lower enzymatic conversion rates by ensuring more substrate reaches the follicle, even if the conversion efficiency remains unchanged.

What Minoxidil Actually Does Inside a Hair Follicle

The mechanism of minoxidil is more interesting than most clinicians give it credit for. The standard shorthand, “vasodilator that increases blood flow to the scalp,” is reductive to the point of being misleading. While minoxidil sulfate does open potassium channels and promote vasodilation, the hair-growth effect operates through at least three distinct molecular pathways that have little to do with bulk blood flow.

First, there’s the direct action on dermal papilla cells. In vitro studies have demonstrated that minoxidil promotes proliferation of cultured human dermal papilla cells in a dose-dependent manner, with proliferation increasing by 60% at 0.01 micromolar concentration and by 108% at 1.0 micromolar after five days of treatment (Han et al., Journal of Dermatological Science, 2004). These cells form the signaling hub of the hair follicle, and their survival and proliferative capacity directly determine follicle health. Minoxidil promotes their survival by activating both the ERK and Akt signaling cascades and by shifting the balance of Bcl-2 (anti-apoptotic) to Bax (pro-apoptotic) proteins in favor of cell survival. The dose-dependence of this effect matters: more minoxidil reaching the dermal papilla means more proliferative signaling, up to a saturation point.

Second, minoxidil drives vascular endothelial growth factor (VEGF) expression. Lachgar and colleagues at INSERM showed in 1998 that dermal papilla cells incubated with increasing minoxidil concentrations from 0.2 to 24 micromoles per liter produced VEGF mRNA in a clear dose-dependent fashion (Journal of Investigative Dermatology, 1998). This VEGF upregulation promotes perifollicular angiogenesis, building the capillary network that supports the metabolically demanding anagen phase. Subsequent work revealed that minoxidil induces VEGF through inhibition of HIF-prolyl hydroxylase, stabilizing HIF-1 alpha even under normoxic conditions (Yum et al., Experimental Dermatology, 2018). The practical implication: the molecular machinery that drives minoxidil’s benefit responds to concentration gradients in a way that suggests a simple 5% ceiling may not capture the full therapeutic potential.

Third, there’s emerging evidence that minoxidil activates Wnt/beta-catenin signaling in dermal papilla cells, a pathway fundamental to hair follicle development and cycling. VEGF itself can feed into beta-catenin activation, creating a reinforcing loop between angiogenesis and follicular regeneration. These interconnected pathways help explain why minoxidil can sometimes reverse miniaturization of vellus hairs back to terminal hairs, not merely slow further loss.

The Clinical Evidence Above 5%

The most frequently cited head-to-head trial comparing concentrations above 5% is the Ghonemy, Alarawi, and Bessar study, a 36-week double-blinded, placebo-controlled trial published in the Journal of Dermatological Treatment in 2021. Ninety men with androgenetic alopecia were randomized to 5% minoxidil solution, 10% minoxidil solution, or placebo. The results surprised many observers: the 5% group showed superior hair regrowth compared to the 10% group, with significantly better changes from baseline in both vertex and frontal hair counts. The 10% group still outperformed placebo, but 10% also produced markedly more scalp irritation than 5%.

Does this settle the question? Not really, and here’s why. The 10% formulation in that trial used a standard ethanol-propylene glycol vehicle designed for 5% concentrations. At 10%, minoxidil is pushing against its solubility limits in conventional solvents. Crystallization on the scalp surface is well documented at concentrations above 5% in standard vehicles (Singh et al., Clinical and Experimental Dermatology, 2022). Crystals sitting on skin don’t penetrate follicles. The irritation likely came from the vehicle struggling to keep the drug in solution at higher loads rather than from minoxidil itself, and the inferior efficacy results may reflect poor bioavailability rather than a true pharmacological plateau.

This is precisely where the vehicle question becomes central. A 2023 study examining transfersome-loaded minoxidil formulations demonstrated that lipid-based nanocarriers could dramatically increase both epidermal penetration and follicular targeting compared to conventional solutions (Zeb et al., Journal of Drug Delivery Science and Technology, 2023). Nanoemulsions containing eucalyptol or oleic acid have shown significantly greater skin permeation of minoxidil compared to control solutions, with oleic acid formulations producing the highest hair follicle penetration specifically (Gomes et al., Pharmaceutics, 2018). The 5% minoxidil foam, which eliminated propylene glycol from the vehicle, showed five-fold greater minoxidil uptake over the standard 5% solution at two hours in a hamster ear model (Olsen et al., Journal of the American Academy of Dermatology, 2007). If the vehicle makes that much difference at 5%, it’s reasonable to expect that properly formulated higher concentrations could deliver meaningfully better results than the Ghonemy trial’s alcohol-based 10% solution achieved.

A review by Singh and colleagues published in Clinical and Experimental Dermatology in 2022 systematically examined whether concentrations above 5% provide clinical benefit. Their conclusion was cautious but telling: the evidence base is thin, limited by small sample sizes and formulation inconsistencies, but the pharmacological rationale for dose-dependent benefit remains sound. The problem isn’t that higher concentrations don’t work. The problem is that we haven’t yet run the right trials with the right formulations.

The Enzyme Lottery: Why Your Genetics Determine Whether Minoxidil Works

Perhaps the most compelling argument for individualized concentration comes from pharmacogenomics. The SULT1A1 gene encodes the sulfotransferase enzyme that converts minoxidil to its active sulfate form in hair follicles, and activity levels of this enzyme vary enormously between individuals. A landmark study by Roberts and colleagues developed an enzymatic assay that could predict minoxidil response with 95% sensitivity and 73% specificity by measuring SULT1A1 activity in plucked hair follicles (Experimental Dermatology, 2014). Patients with high follicular sulfotransferase activity were far more likely to respond to standard-dose minoxidil; those with low activity were the non-responders that clinicians had puzzled over for years.

The genetic dimension deepens the picture. SULT1A1 has known polymorphisms: the GG genotype correlates with high enzymatic activity and strong minoxidil response, while the AA genotype predicts low activity and poor outcomes (Goren et al., Dermatologic Therapy, 2020). This turns the question of concentration into a precision medicine problem. A patient with high SULT1A1 activity may do well at 2%, let alone 5%. A patient with the AA genotype and low follicular enzyme activity might need a substantially higher substrate concentration to produce enough minoxidil sulfate for therapeutic effect.

A 2024 study by Jimenez-Cauhe and colleagues added an intriguing wrinkle. In 41 patients treated with low-dose oral minoxidil for six months, those with low hair follicle SULT activity paradoxically showed higher response rates (85%) than those with high enzyme activity (43%) (Journal of Cosmetic Dermatology, 2024). The authors proposed that systemic delivery bypasses the follicular enzyme bottleneck entirely, since hepatic sulfotransferases handle the conversion instead. This finding strengthens the case that topical non-responders are failing at the local enzyme conversion step, not at the receptor level, and that getting more drug into the follicle through higher topical concentrations or better vehicles could achieve results similar to what oral dosing achieves through a different route.

Approaches to boost SULT1A1 activity directly are also showing promise. A clinical study found that 75% of subjects using a SULT1A1 adjuvant alongside daily minoxidil regrew hair over 60 days, compared to 33% using placebo adjuvant (Goren et al., Journal of Cosmetic Dermatology, 2021). Tretinoin applied topically for five days converted 43% of predicted non-responders into responders, likely by upregulating sulfotransferase expression in the outer root sheath.

The Regulatory Split Between Canada and the United States

The practical availability of higher-concentration minoxidil depends heavily on where you live. In the United States, the FDA’s OTC monograph caps topical minoxidil at 5%. Concentrations above that threshold can only be obtained through compounding pharmacies with a prescription, placing them outside the standard regulatory pathway and insurance coverage. The FDA has shown no interest in expanding the monograph, partly because no manufacturer has invested in the large Phase III trials that would be required for a new OTC concentration.

Canada’s regulatory framework under Health Canada operates differently. While the standard OTC monograph similarly covers concentrations up to 5%, the pathway for higher-concentration products is more flexible. Health Canada’s Drug Products Database and Natural and Non-prescription Health Products Directorate allow for registration of higher-concentration formulations through appropriate regulatory channels. This means Canadian patients and clinicians have access to 7% and higher-concentration topical minoxidil products through legitimate pharmaceutical channels rather than relying solely on compounding, providing manufactured consistency and quality control that compounded preparations sometimes lack.

Scalp Tolerance and Systemic Safety at Higher Concentrations

The safety question at concentrations above 5% deserves honest treatment. On average, only about 1.4% of topically applied minoxidil is absorbed systemically (Badri et al., StatPearls, 2024). Even at 10%, systemic levels remain well below those associated with the cardiovascular effects seen at oral therapeutic doses (typically 10 to 40 mg daily for hypertension). No published study on higher-concentration topical formulations has reported clinically significant cardiovascular effects, including hypotension, tachycardia, or fluid retention.

Local side effects are a different story. The Ghonemy trial documented increased scalp irritation at 10% in a conventional vehicle, and this tracks with the broader literature on propylene glycol as a sensitizer. Propylene glycol causes irritant contact dermatitis in a significant minority of patients even at standard concentrations, and patch testing has confirmed that most topical minoxidil allergic reactions are to propylene glycol rather than minoxidil itself (Friedman et al., Journal of the American Academy of Dermatology, 2002). Propylene glycol-free formulations, whether foam-based or using alternative vehicles like glycerin or butylene glycol, substantially reduce this problem. One survey found that 62% of dermatologists reported better tolerability with alcohol-free minoxidil vehicles. Hypertrichosis, or unwanted hair growth on the face or body, does increase somewhat with higher concentrations and is more commonly reported in women, but remains manageable with careful application technique.

The implication is clear: the tolerability issues attributed to higher concentrations are largely vehicle problems, not drug problems. A well-formulated 7% minoxidil in a modern vehicle may actually be better tolerated than a 5% solution in a traditional ethanol-propylene glycol base.

Where This Is Heading

The convergence of pharmacogenomic testing, advanced drug delivery systems, and clinical demand from the large pool of 5% non-responders points toward a future where minoxidil concentration is individualized rather than capped at a regulatory artifact from 1991. The evidence supporting dose-dependent cellular responses is strong at the bench level. The clinical trial data at higher concentrations is limited but growing, and its limitations have more to do with outdated vehicles than with the drug itself. The SULT1A1 testing story offers a rational framework for matching patients to concentrations based on their enzymatic phenotype rather than defaulting everyone to the same dose.

What’s needed now is straightforward: well-designed, adequately powered trials of higher-concentration minoxidil in modern formulations, ideally stratified by SULT1A1 activity, with trichoscopic endpoints and at least 48 weeks of follow-up. Several such studies are in early stages or planning across North American and European centers. Until those results arrive, clinicians working with patients who’ve failed standard 5% therapy have a reasonable pharmacological basis for considering higher concentrations, particularly in jurisdictions like Canada where such products are available through regulated channels. The 5% ceiling was never a pharmacological conclusion. It was a regulatory one, and the science is finally catching up with the question of what happens when you go higher.

References

  1. Olsen EA, et al. “A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.” Journal of the American Academy of Dermatology. 2002;47(3):377-385. DOI: 10.1067/mjd.2002.124088

  2. Badri T, Nessel TA, Kumar DD. “Minoxidil.” StatPearls. 2024. PMID: 29763070

  3. Han JH, et al. “Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle.” Journal of Dermatological Science. 2004;34(2):91-98. DOI: 10.1016/j.jdermsci.2004.01.002

  4. Lachgar S, et al. “Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells.” British Journal of Dermatology. 1998;138(3):407-411. DOI: 10.1046/j.1365-2133.1998.02115.x

  5. Yum S, et al. “Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase.” Experimental Dermatology. 2018;27(Suppl 1):31-33. PMID: 29377322

  6. Ghonemy S, Alarawi A, Bessar H. “Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.” Journal of Dermatological Treatment. 2021;32(2):236-241. DOI: 10.1080/09546634.2019.1654070

  7. Singh S, et al. “Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit?” Clinical and Experimental Dermatology. 2022;47(11):1951-1955. DOI: 10.1111/ced.15338

  8. Zeb A, et al. “The preparation of high minoxidil loaded transfersomes and its gel for effective topical treatment of alopecia.” Journal of Drug Delivery Science and Technology. 2023;86:104741.

  9. Gomes MJ, et al. “Minoxidil Skin Delivery from Nanoemulsion Formulations Containing Eucalyptol or Oleic Acid: Enhanced Diffusivity and Follicular Targeting.” Pharmaceutics. 2018;10(3):E146. DOI: 10.3390/pharmaceutics10030146

  10. Roberts J, et al. “Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia.” Experimental Dermatology. 2014;23(Suppl 1):27. DOI: 10.1111/exd.12283

  11. Goren A, et al. “Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss.” Dermatologic Therapy. 2020;33(4):e13756. DOI: 10.1111/dth.13756

  12. Jimenez-Cauhe J, et al. “Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia.” Journal of Cosmetic Dermatology. 2024;23(9):2884-2889. DOI: 10.1111/jocd.16473

  13. Goren A, et al. “SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth.” Journal of Cosmetic Dermatology. 2021;20(Suppl 1):33-34. DOI: 10.1111/jocd.14311

  14. Friedman ES, et al. “Allergic contact dermatitis to topical minoxidil solution: etiology and treatment.” Journal of the American Academy of Dermatology. 2002;46(2):309-312. DOI: 10.1067/mjd.2002.119104

  15. Messenger AG, Rundegren J. “Minoxidil: mechanisms of action on hair growth.” British Journal of Dermatology. 2004;150(2):186-194. DOI: 10.1111/j.1365-2133.2004.05785.x